Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
PYC Therapeutics Limited ( (AU:PYC) ) has shared an update.
PYC Therapeutics announced positive safety outcomes from Part A of its Phase 1a/1b single-ascending-dose clinical trial of PYC-003, reporting that single doses up to 4 mg/kg in healthy volunteers were safe and well tolerated with no treatment-emergent serious adverse events. Based on these data, the company has begun dosing PKD patients in Part B of the study at 1.2 mg/kg and is preparing to initiate a repeat-dose Part C in the first half of 2026, positioning PYC-003 to progress into a planned single registrational Phase 2/3 trial aimed at supporting a future new drug application and advancing its strategy in the PKD treatment landscape.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is an ASX-listed precision medicine company focused on developing treatments for genetic diseases with no existing therapies. The company currently has three clinical-stage drug development programs, including PYC-003, a candidate targeting the underlying cause of autosomal dominant polycystic kidney disease (PKD).
Average Trading Volume: 538,865
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$869.1M
Find detailed analytics on PYC stock on TipRanks’ Stock Analysis page.